Enterprise Bank & Trust Co Has $438,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

Enterprise Bank & Trust Co cut its holdings in Biogen Inc. (NASDAQ:BIIB) by 28.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,864 shares of the biotechnology company’s stock after selling 1,138 shares during the quarter. Enterprise Bank & Trust Co’s holdings in Biogen were worth $438,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. International Assets Investment Management LLC boosted its holdings in shares of Biogen by 19,722.9% in the 3rd quarter. International Assets Investment Management LLC now owns 358,992 shares of the biotechnology company’s stock valued at $695,870,000 after buying an additional 357,181 shares during the last quarter. Mizuho Securities USA LLC raised its stake in Biogen by 2,715.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 316,000 shares of the biotechnology company’s stock valued at $61,253,000 after acquiring an additional 304,778 shares during the period. Erste Asset Management GmbH bought a new stake in Biogen in the 3rd quarter valued at $55,826,000. State Street Corp raised its stake in Biogen by 3.5% in the 3rd quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company’s stock valued at $1,423,747,000 after acquiring an additional 248,942 shares during the period. Finally, Two Sigma Advisers LP raised its stake in Biogen by 122.1% in the 3rd quarter. Two Sigma Advisers LP now owns 427,600 shares of the biotechnology company’s stock valued at $82,886,000 after acquiring an additional 235,100 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Trading Up 0.5 %

Shares of BIIB stock traded up $0.76 during mid-day trading on Monday, reaching $149.58. 702,184 shares of the stock traded hands, compared to its average volume of 1,098,673. The stock’s fifty day simple moving average is $157.38 and its two-hundred day simple moving average is $187.29. Biogen Inc. has a 1-year low of $145.07 and a 1-year high of $252.17. The company has a market cap of $21.80 billion, a price-to-earnings ratio of 13.51, a price-to-earnings-growth ratio of 1.74 and a beta of -0.07. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.31. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.43 billion. During the same period last year, the firm posted $4.36 earnings per share. The business’s revenue for the quarter was down 2.5% on a year-over-year basis. On average, research analysts anticipate that Biogen Inc. will post 16.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BIIB. Jefferies Financial Group cut Biogen from a “buy” rating to a “hold” rating and dropped their price target for the company from $250.00 to $180.00 in a research note on Monday, December 9th. Stifel Nicolaus cut Biogen from a “buy” rating to a “hold” rating and set a $175.00 price objective on the stock. in a research report on Monday, December 16th. Wedbush lowered their price objective on Biogen from $210.00 to $205.00 and set a “neutral” rating on the stock in a research report on Monday, September 23rd. Wells Fargo & Company lowered their price objective on Biogen from $190.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Friday. Finally, Royal Bank of Canada lowered their price objective on Biogen from $292.00 to $269.00 and set an “outperform” rating on the stock in a research report on Friday, October 4th. Sixteen analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $230.00.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.